BioPharmSignal logoBioPharmSignal

Biotech News

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Kiora Pharmaceuticals (KPRX)Kiora PharmaceuticalsPartnership

KPRX (KPRX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is kprx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

KPRXKiora Pharmaceuticals2026-04-14 11:00 EST

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

LENZLenz Therapeutics Inc2026-06-24 12:30 EST

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

MGTXMeiraGTx2025-11-10 12:00 EST

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

KPRXKiora Pharmaceuticals2026-05-08 11:00 EST

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

LCTXLineage Cell Therapeutics2025-11-24 16:20 EST

Lineage Achieves First Milestone Under Worldwide Collaboration Agreement with Genentech

TARSTarsus Pharmaceuticals2026-05-14 12:30 EST

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

IRIXIRIDEX2026-04-07 20:05 EST

Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology

LENZLenz Therapeutics Inc2026-01-05 13:00 EST

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

LCTXLineage Cell Therapeutics2026-01-06 13:00 EST

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

VRDNViridian Therapeutics2022-01-31 12:00 EST

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

View all latest news

Kiora Pharmaceuticals

Kiora Pharmaceuticals is a biotechnology company focused on ophthalmology and retinal disease. Its story is centered on developing treatments for eye diseases where local delivery and specialized biology matter.

Recent company news

KPRXKiora Pharmaceuticals2026-07-02 11:00 EST

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

KPRXKiora Pharmaceuticals2026-06-18 11:00 EST

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

KPRXKiora Pharmaceuticals2026-05-08 11:00 EST

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

KPRXKiora Pharmaceuticals2026-04-14 11:00 EST

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

KPRXKiora Pharmaceuticals2026-04-07 11:00 EST

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

Stock data

Close
2.54 USD
Market cap
12.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States